Celltrion’s Eydenzelt Shows Long-Term Efficacy, Accelerates $13B Market Entry 송영두 2025.09.03 오전 09:01 Celltrion Posts Record Q2 Results, Accelerates Global Pharma Ambitions 나은경 2025.07.24 오전 10:58 AI Diagnostics Poised to Elevate K-Bio’s Global Standing 류성 2025.07.15 오전 07:40 Celltrion to Buy Back ￦100B More, 2024 Total Hits ￦650B 김새미 2025.06.26 오전 10:25 1년간 주가 150% 폭등 삼천당제약,사라진 1등출시 가능성 송영두 2023.04.13 오전 09:20 The Achilles’ Heel of Korea’s Biopharma Giants[Yoo Sung’s Pharma National Wealth Theory] 류성 2025.05.15 오전 06:24 Celltrion Unfazed by U.S. Price Cuts, Tariffs Zymfentra Drag Tied to Insurance 송영두 2025.05.15 오후 03:23 Shinpoong Pharm Surges on EU Pyramax Patent; Geninus, Viol Also Rally[K-Bio Pulse] 김새미 2025.06.19 오전 08:34 Celltrion biosimilars expand dominance in Japan’s oncology market 임정요 2025.06.13 오전 10:11 Celltrion Wins FDA Nod for Xolair Biosimilar OMLYCLO 송영두 2025.03.12 오전 10:40 더 보기 로딩중..
biosimilar
biosimilar
![The Achilles’ Heel of Korea’s Biopharma Giants[Yoo Sung’s Pharma National Wealth Theory]](https://image.edaily.co.kr/images/vision/files/NP/S/2025/05/PS25051500174b.jpg)
![Shinpoong Pharm Surges on EU Pyramax Patent; Geninus, Viol Also Rally[K-Bio Pulse]](https://image.edaily.co.kr/images/vision/files/NP/S/2025/06/PS25061900347b.jpg)
